Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (1-10 of 511) with videos related to

Pageof 52
Sort By:
Bulletin Du Cancer|June 30, 2015
[Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes]Benjamin Besse
La Revue Du Praticien|February 11, 2022
[Immunotherapy in oncology]Maxime Frelaut, Benjamin Besse
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of SteroidsBenjamin Besse, Jordi Remon
Bulletin Du Cancer|March 28, 2025
[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression]Antoine Lefèvre, Benjamin Besse
The European Respiratory Journal|May 2, 2015
Lung cancer in never-smokersDavid Planchard, Benjamin Besse
Current Opinion in Oncology|January 7, 2017
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancerJordi Remon, Benjamin Besse
ESMO Open|November 16, 2016
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsJordi Remon, Benjamin Besse
Translational Lung Cancer Research|July 23, 2021
Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative reviewCharles Naltet, Benjamin Besse
Journal of Thoracic Disease|January 10, 2017
Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw <i>et al</i>Laura Mezquita, Benjamin Besse
Frontiers in Oncology|April 27, 2018
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and TreatmentJ Remon, Benjamin Besse
Pageof 52

Showing results (1-10 of 511) with videos related to

Sort By:
Pageof 52
Bulletin Du Cancer|June 30, 2015
[Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes]Benjamin Besse
La Revue Du Praticien|February 11, 2022
[Immunotherapy in oncology]Maxime Frelaut, Benjamin Besse
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of SteroidsBenjamin Besse, Jordi Remon
Bulletin Du Cancer|March 28, 2025
[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression]Antoine Lefèvre, Benjamin Besse
The European Respiratory Journal|May 2, 2015
Lung cancer in never-smokersDavid Planchard, Benjamin Besse
Current Opinion in Oncology|January 7, 2017
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancerJordi Remon, Benjamin Besse
ESMO Open|November 16, 2016
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsJordi Remon, Benjamin Besse
Translational Lung Cancer Research|July 23, 2021
Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative reviewCharles Naltet, Benjamin Besse
Journal of Thoracic Disease|January 10, 2017
Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw <i>et al</i>Laura Mezquita, Benjamin Besse
Frontiers in Oncology|April 27, 2018
Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and TreatmentJ Remon, Benjamin Besse
Pageof 52